康泰医学
(300869)
| 流通市值:23.53亿 | | | 总市值:35.84亿 |
| 流通股本:2.64亿 | | | 总股本:4.02亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 353,739,898.59 | 225,877,603.09 | 100,279,216.75 | 468,004,884.41 |
| 营业收入 | 353,739,898.59 | 225,877,603.09 | 100,279,216.75 | 468,004,884.41 |
| 二、营业总成本 | 394,728,383.53 | 255,161,799.97 | 114,012,396.72 | 496,009,962.87 |
| 营业成本 | 190,081,293.89 | 116,447,191.76 | 48,347,008.24 | 243,142,442.81 |
| 税金及附加 | 4,229,743.23 | 3,216,561.21 | 2,185,955.66 | 7,709,699.75 |
| 销售费用 | 68,327,369.84 | 45,141,581.69 | 19,589,070.3 | 109,966,081.06 |
| 管理费用 | 31,681,500.47 | 20,728,272.98 | 10,638,696.28 | 39,475,990.05 |
| 研发费用 | 66,098,060.1 | 44,757,297.85 | 21,701,198.82 | 91,658,946.04 |
| 财务费用 | 34,310,416 | 24,870,894.48 | 11,550,467.42 | 4,056,803.16 |
| 其中:利息费用 | - | - | - | 37,428,972.59 |
| 其中:利息收入 | - | - | - | 49,801,528.24 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,287,664.2 | 2,327,222.03 | 2,334,068.88 | 1,773,267.48 |
| 加:投资收益 | 8,858,492.32 | 8,367,926.28 | 2,016,982.9 | 16,729,120.38 |
| 资产处置收益 | 0 | - | - | 171.89 |
| 资产减值损失(新) | -31,524,206.1 | -33,668,249.14 | - | -28,148,237.76 |
| 信用减值损失(新) | 153,621.79 | 165,133.6 | 239,253.89 | 1,354,502.84 |
| 其他收益 | 1,064,350.02 | 869,171.47 | 310,190.79 | 9,963,375.98 |
| 四、营业利润 | -60,148,562.71 | -51,222,992.64 | -8,832,683.51 | -26,332,877.65 |
| 加:营业外收入 | 1,385,479.02 | 773,046.52 | 273,863.32 | 1,086,164.45 |
| 减:营业外支出 | 366,495.89 | 164,639.88 | 152,586.65 | 1,639,226.21 |
| 五、利润总额 | -59,129,579.58 | -50,614,586 | -8,711,406.84 | -26,885,939.41 |
| 减:所得税费用 | -1,847,127.08 | -1,346,602.72 | -469,636.88 | -2,462,078.36 |
| 六、净利润 | -57,282,452.5 | -49,267,983.28 | -8,241,769.96 | -24,423,861.05 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -57,282,452.5 | -49,267,983.28 | -8,241,769.96 | -24,423,861.05 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -57,282,452.5 | -49,267,983.28 | -8,241,769.96 | -24,423,861.05 |
| 扣除非经常损益后的净利润 | -68,515,131.56 | -59,602,413.58 | -12,231,865.25 | -47,342,312.74 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.14 | -0.12 | -0.02 | -0.06 |
| (二)稀释每股收益 | -0.14 | -0.12 | -0.02 | -0.06 |
| 八、其他综合收益 | -1,931,421.5 | -1,472,891.17 | -806,737.63 | -625,845.49 |
| 归属于母公司股东的其他综合收益 | -1,931,421.5 | -1,472,891.17 | -806,737.63 | -625,845.49 |
| 九、综合收益总额 | -59,213,874 | -50,740,874.45 | -9,048,507.59 | -25,049,706.54 |
| 归属于母公司股东的综合收益总额 | -59,213,874 | -50,740,874.45 | -9,048,507.59 | -25,049,706.54 |
| 公告日期 | 2026-10-30 | 2026-08-28 | 2026-04-28 | 2026-04-28 |
| 审计意见(境内) | | | | 标准无保留意见 |